COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof.

Allulose epimerase variant, method for preparing the same, and method for preparing allulose using the same

The present invention provides: a novel allulose epimerase variant in which an amino acid residue present at a specific position of an amino acid sequence of a wild-type D-allulose 3-epimerase derived from Flavonifractor plautii is substituted with another amino acid residue; and various uses of the novel allulose epimerase variant. The novel allulose epimerase variant according to the present invention has a higher conversion rate of fructose to allulose compared to that of the wild-type D-allulose 3-epimerase derived from Flavonifractor plautii, and has excellent thermal stability especially under high temperature conditions of 60° C. or higher, and thus can prevent contamination during an industrial-scale enzymatic conversion reaction for the mass production of allulose, shorten production time, and reduce production costs.

COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof. 157-. (canceled)58. A composition for cleaving a target nucleic acid sequence in a eukaryotic cell , the composition comprising a Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas system in a eukaryotic cell , wherein the Type II CRISPR/Cas system comprises:a) a nucleic acid encoding a Cas9 polypeptide, andb) a nucleic acid encoding a guide RNA that hybridizes with the target nucleic acid sequence,wherein the Cas9 polypeptide and the guide RNA form a Cas9/RNA complex in the eukaryotic cell and wherein the guide RNA has sufficient sequence complementarity to the target nucleic acid sequence in the eukaryotic cell to allow the Cas9 polypeptide to mediate double stranded cleavage at the target nucleic acid sequence.59. The composition of claim 58 , wherein the Cas9 polypeptide further comprises a nuclear localization signal.60. The composition of claim 58 , wherein the nuclear localization signal is located at the C terminus of the Cas9 polypeptide.61. The composition of claim 58 , wherein the eukaryotic cell is a mammalian cell.62. The composition of claim 58 , wherein the mammalian cell is a human cell.63. The composition of claim 58 , wherein the nucleic acid encoding the Cas9 polypeptide is codon-optimized for expression in eukaryotic cells.64. The composition of claim 58 , wherein the target nucleic acid sequence is a genomic sequence located at its endogenous site in the genome of the eukaryotic cell.65. The composition of claim 58 , wherein the nucleic acid encoding the Cas9 polypeptide is a vector.66. The composition of claim 65 , wherein the nucleic acid encoding the guide RNA is a vector.67. The ...

HYDROGEL USING, AS SUBSTRATE, HYALURONIC ACID DERIVATIVE MODIFIED WITH GALLOL GROUP AND USE THEREOF

The present invention provides a hydrogel platform using, as a substrate, hyaluronic acid (HA) conjugated to a pyrogallol (PG) moiety. The HA-PG conjugate of the present invention can be rapidly crosslinked by two different methods, in each of which an oxidizing agent is used or a pH is adjusted. The hydrogel of the present invention can not only have excellent biocompatibility, but also can have efficiently controlled physical characteristics such as a crosslinking rate, elasticity, and adhesive strength, depending on each crosslinking method. On the basis of such excellent stability and functionality, the hydrogel of the present invention can be used in various fields including drug delivery, biopharmaceutical materials such as a wound healing agent or anti-adhesive agent, medicines, and cosmetic products. 1. A method for preparing a hyaluronic acid hydrogel , comprising:a step of crosslinking hyaluronic acid derivatives, each of which is modified with a pyrogallol group,wherein in the hyaluronic acid derivative, hyaluronic acid has been modified with a pyrogallol group.32. The method according to of claim 1 ,wherein in the crosslinking step, crosslinking is carried out by adding an oxidizing agent or a pH adjusting agent.4. The method according to claim 3 ,wherein the oxidizing agent is any one selected from the group consisting of sodium periodate, hydrogen peroxide, horseradish peroxidase, and tyrosinase.6. The method according to claim 3 ,wherein the pH adjusting agent is any one selected from the group consisting of sodium hydroxide, lithium hydroxide, potassium hydroxide, rubidium hydroxide, cesium hydroxide, magnesium hydroxide, calcium hydroxide, strontium hydroxide, and barium hydroxide.9. The hyaluronic acid hydrogel according to claim 8 ,wherein the hyaluronic acid derivative has a molecular weight of 10,000 Da to 2,000,000 Da.10. The hyaluronic acid hydrogel according to claim 8 ,wherein the hyaluronic acid derivative has a gallol group substitution ...

Ultra high voltage direct current power cable system

An ultra-high-voltage DC power cable system capable of simultaneously preventing or minimizing electric field distortion, a reduction of DC dielectric strength, and a reduction of impulse breakdown strength due to the accumulation of space charges in an insulating layer of a cable and an insulating material of an intermediate connection part.

Intermediate connection structure of power cable

The present disclosure relates to a power cable and an intermediate connection structure, for connection thereof, which is capable of preventing the concentration of stress on a soldered part, which is configured to join a metal sheath of the power cable and a metal sheath restoration layer of the intermediate connection structure while ensuring airtight or watertight sealing therebetween, preventing deformation of or damage to the soldered part due to stress applied thereto, and minimizing thermal history in the power cable during the formation of the soldered part.

Method for cell-free protein complete post-translational modification

The present invention relates to methods of production of the completely post-translationally modified protein by combination of cell-free protein synthesis and cell-free co- and post-translational modification. Previous cell-free protein synthesis system has only been capable of producing partially post-translationally modified protein but the present invention employs a co- and post-translational modification machinery that produces completely post-translationally modified protein.

COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof. 157-. (canceled)60. The method of claim 59 , wherein the two nicks are separated by at least 100 base pairs.61. The method of claim 58 , wherein the CRISPR/Cas9 complex is introduced by transfection claim 58 , wherein the transfection is performed by the method selected from the group consisting of microinjection claim 58 , electroporation claim 58 , DEAE-dextran treatment claim 58 , lipofection claim 58 , nanoparticle-mediated transfection claim 58 , protein transduction domain mediated transduction claim 58 , virus-mediated gene delivery claim 58 , or polyethylene glycol (PEG)-mediated transfection of protoplasts.62. The method of wherein the transfection is by PEG-mediated transfection of protoplasts in a 40% PEG transfection buffer.63. The method of claim 62 , wherein the 40% PEG transfection buffer comprises 40% PEG4000 claim 62 , 200 mM mannitol and 100 mM CaCl.64Streptococcus.. The method of claim 58 , wherein the Cas9 protein is from the genus65Streptococcus pyogenes.. The method of or claim 58 , wherein the Cas9 protein is from66. The method of claim 59 , wherein the Cas9 nickase is a mutant form of Cas9 claim 59 , in which the catalytic aspartate residue is changed to alanine.67. The method of claim 58 , wherein the Cas9 polypeptide comprises a nuclear localization signal (NLS).68. The method of claim 58 , wherein the crRNA comprises two additional nucleotides at its 5′ end claim 58 , wherein the two additional nucleotides are guanine nucleotides.69. The method of claim 58 , wherein the crRNA is 20 nucleotides in length.70. The method of claim 58 , wherein the target DNA is genomic DNA.71. The method of claim 58 , wherein ...

Intermediate connection system for ultra-high-voltage direct current power cable

Provided is an intermediate connection system for an ultra-high-voltage direct-current (DC) power cable. Specifically, the present invention relates to an intermediate connection system, for an ultra-high-voltage DC power cable, which is capable of simultaneously preventing or minimizing electric field distortion, a decrease of DC dielectric strength, and a decrease of impulse breakdown strength due to the accumulation of space charges in an insulating layer of a cable and an insulating material of an intermediate connection part.

Methods for cleaving a target DNA using a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof.

COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof. 157-. (canceled)58. A composition for cleaving a target nucleic acid sequence in a mammalian cell , the composition comprising a Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas system in the mammalian cell , wherein the Type II CRISPR/Cas system comprises:a) a nucleic acid encoding a Cas9 polypeptide, wherein the Cas9 polypeptide comprises a nuclear localization signal, andb) a chimeric guide RNA comprising a CRISPR RNA (crRNA) portion fused to a trans activating crRNA (tracrRNA) portion,wherein the Cas9 polypeptide and the chimeric guide RNA form a Cas9/RNA complex in the mammalian cell and wherein the crRNA portion has sufficient sequence complementarity to the target nucleic acid sequence in the mammalian cell to allow the Cas9 polypeptide to mediate double stranded cleavage at the target nucleic acid sequence.59. The composition of claim 58 , wherein the nuclear localization signal is located at the C terminus of the Cas9 polypeptide.60. The composition of claim 58 , wherein the mammalian cell is a human cell.61. The composition of claim 58 , wherein the nucleic acid encoding the Cas 9 polypeptide is codon-optimized for expression in mammalian cells.62. The composition of claim 58 , wherein the chimeric guide RNA is in vitro transcribed RNA.63. The composition of claim 58 , wherein the target nucleic acid sequence is a genomic sequence located at its endogenous site in the genome of the mammalian cell.64Streptococcus pyogenes. The composition of claim 58 , wherein the Cas9 polypeptide is a Cas9 polypeptide.65. The composition of claim 58 , wherein the target nucleic acid sequence consists of 20 ...

Highly efficient organoid culture device and system

The present invention provides an organoid culture device, comprising at least one first chamber for storing a culture medium; at least one second chamber for culturing an organoid; and a channel that interconnects adjacent chambers.

DEVICE AND METHOD FOR REMOVING HARMONIC COMPONENTS

An apparatus of a Harmonic Rejection Mixer (HRM) for removing a harmonic component and an operating method thereof are provided. The HRM includes a Local Oscillator (LO), at least one frequency converter, at least two mixers, at least one phase converter, and a combiner. The LO generates an LO signal. The at least one frequency converter multiplies the LO signal using different variables to provide the same to at least two mixers. The at least two mixers convert a frequency band of an input signal using the LO signal provided from the LO and the at least one frequency converter. The at least one phase converter controls a phase of an output signal of at least one other mixer excluding one of the at least two mixers. The combiner combines an output signal of the one mixer with an output signal of the at least one phase converter. 1. An apparatus of a Harmonic Rejection Mixer (HRM) for removing a harmonic component , the apparatus comprising:a Local Oscillator (LO) for generating a Local Oscillation (LO) signal;at least one frequency converter for multiplying the LO signal using different variables to provide the same to at least one mixer;at least two mixers for converting a frequency band of an input signal using the LO signal provided from the LO and the at least one frequency converter;at least one phase converter for controlling a phase of an output signal of at least one other mixer excluding one of the at least two mixers; anda combiner for combining an output signal of the one mixer with an output signal of the at least one phase converter.2. The apparatus of claim 1 , further comprising:at least one attenuator for controlling a magnitude of an output signal of the at least one other mixer so that a magnitude of a harmonic component included in an output signal of the one mixer is the same as a magnitude of an output signal of the at least one other mixer,wherein the at least one phase converter controls a phase of a signal provided from the at least one ...

Ultra high voltage direct current power cable system

Provided is an ultra-high-voltage direct-current (DC) power cable system. Specifically, the present disclosure relates to an ultra-high-voltage DC power cable system capable of simultaneously preventing or minimizing electric field distortion, a reduction of DC dielectric strength, and a reduction of impulse breakdown strength due to the accumulation of space charges in an insulating layer of a cable and an insulating material of an intermediate connection part.

Ultrasound image device and ultrasound image generation method

A method of generating an ultrasound image includes: setting a focal point in an object; transmitting, based on a location of the focal point, ultrasound signals into the object by using a plurality of elements in a transducer; receiving, via the plurality of elements, ultrasound echo signals obtained by reflecting the ultrasound signals from the object; and performing beamforming on the received ultrasound echo signals, wherein the performing of the received ultrasound echo signals includes: setting, based on the location of the focal point, a plurality of delay times respectively corresponding to the plurality of elements; determining capacitors respectively corresponding to the plurality of elements based on the set plurality of delay times; and respectively performing the beamforming on the received ultrasound echo signals by using the determined capacitors.

HYDROGEL COMPRISING HYALURONIC ACID MODIFIED BY SEROTONIN AND USES THEREOF

The present disclosure relates to a hydrogel comprising hyaluronic acid modified by serotonin, a use thereof, and a method of preparing the same. 1. A hydrogel including hyaluronic acid modified with serotonin.3. The hydrogel of claim 1 ,wherein the hydrogel is one in which the modified hyaluronic acid is cross-linked by chemical bonding between 5-hydroxyindole moieties of the serotonin.4. The hydrogel of claim 1 ,wherein the hydrogel is adhesive or biodegradable.5. A hemostatic agent composition including the hydrogel of .6. The hemostatic agent composition of claim 5 ,wherein the hemostatic agent has a tissue adhesion inhibiting effect.7. The hemostatic agent composition of claim 5 ,wherein the hemostatic agent is in the form of an adhesive patch or a film.8. A tissue adhesive composition including the hydrogel of .9. The tissue adhesive composition of claim 8 ,wherein the tissue adhesive has a tissue adhesion inhibiting effect.10. A composition for promoting cell differentiation including the hydrogel of .11. The composition for promoting cell differentiation of claim 10 ,wherein the cell is stem cell, fetal stem cell, induced pluripotent stem cell, embryonic stem cell or adult stem cell.12. A composition for cell culture including the hydrogel of .13. The composition for cell culture of claim 12 ,wherein the culture is a three-dimensional culture.14. A composition for drug delivery including the hydrogel of .15. The composition for drug delivery of claim 14 ,wherein the drug is encapsulated in the hydrogel.16. The composition for drug delivery of claim 14 ,wherein the drug is selected from the group consisting of an immune cell activator, an anticancer agent, a therapeutic antibody, an antibiotic, an antibacterial agent, an antiviral agent, an anti-inflammatory agent, a contrast medium, a protein drug, a growth factor, a cytokine, a peptide drug, a hair growth solution and combinations thereof.17. The composition for drug delivery of claim 14 ,wherein the ...

BIO-INSPIRED TISSUE-ADHESIVE HYDROGEL PATCH AND USES THEREOF

The present disclosure relates to a catechol group- or pyrogallol group-functionalized biocompatible polymer hydrogel patch having excellent biocompatibility and tissue adhesion, and uses for drug delivery, cell transplantation and tissue regeneration using the same. The biocompatible polymer hydrogel patch functionalized with the catechol group or pyrogallol group of the present disclosure has remarkably excellent mechanical properties and tissue adhesion compared with a solution-based bulk hydrogel. Therefore, it can load cells and a drug in vivo for a long time and also safely and efficiently deliver the cells and the drug to a target site. 1. A hydrogel patch comprising a biocompatible polymer functionalized with a catechol group or a pyrogallol group.2. The hydrogel patch of claim 1 ,wherein the catechol group is derived from a catechol-based compound selected from the group consisting of catechol, 4-tert-butylcatechol (TBC), urushiol, alizarin, dopamine, dopamine hydrochloride, 3,4-dihydroxyphenylalanine (DOPA), caffeic acid, norepinephrine, epinephrine, 3,4-dihydroxyphenylacetic acid (DOPAC), isoprenaline, isoproterenol and 3,4-dihydroxybenzoic acid, andthe pyrogallol group is derived from a pyrogallol-based compound selected from the group consisting of pyrogallol, 5-hydroxydopamine, tannic acid, gallic acid, epigallocatechin, epicatechin gallate, epigallocatechin gallate, 2,3,4-trihydroxybenzaldehyde, 2,3,4-trihydroxybenzoic acid, 3,4,5-trihydroxybenzaldehyde, 3,4,5-trihydroxybenzamide, 5-tert-butylpyrogallol and 5-methylpyrogallol.3. The hydrogel patch of claim 1 ,wherein the biocompatible polymer is selected from the group consisting of hyaluronic acid, heparin, cellulose, dextran, alginate, chitosan, chitin, collagen, gelatin, chondroitin sulfate, pectin, keratin and fibrin.4. The hydrogel patch of claim 1 ,wherein the hydrogel patch has a thickness of from 0.05 mm to 10.0 mm.5. A drug delivery system claim 1 , comprising:{'claim-ref': {'@idref': 'CLM- ...

Intermediate connection system for ultra-high-voltage direct current power cable

Provided is an intermediate connection system for an ultra-high-voltage direct-current (DC) power cable. Specifically, the present invention relates to an intermediate connection system, for an ultra-high-voltage DC power cable, which is capable of simultaneously preventing or minimizing electric field distortion, a decrease of DC dielectric strength, and a decrease of impulse breakdown strength due to the accumulation of space charges in an insulating layer of a cable and an insulating material of an intermediate connection part.

Artificial tissue for transplantation therapy, drug screening, Manufacturing method thereof, and Manufacturing apparatus therefor

Present disclosure provides an apparatus for manufacturing an artificial tissue, comprising: a hydrogel accommodating structure which accommodates hydrogel including cells and has a bottom plate, a container and a cover; and a standing wave adding means for adding a standing wave to the hydrogel accommodated in the hydrogel accommodating structure, wherein cells in the hydrogel are aligned by the adding of a standing wave, and the position of the cells in the hydrogel is controlled by adjusting at least one of the attenuation coefficient of the container and the reflection coefficient of the cover. 1. An apparatus for manufacturing an artificial tissue , comprising:a hydrogel accommodating structure which accommodates hydrogel including cells and has a bottom plate, a container and a cover; anda standing wave adding means for adding a standing wave to the hydrogel accommodated in the hydrogel accommodating structure,wherein cells in the hydrogel are aligned by the adding of a standing wave, and the position of the cells in the hydrogel is controlled by adjusting at least one of the attenuation coefficient of the container and the reflection coefficient of the cover.2. The apparatus of claim 1 , wherein the hydrogel accommodating structure is detachable claim 1 , and is disassembleable into the bottom plate claim 1 , the container and the cover.3. The apparatus of claim 1 , wherein the container is made of a material attachable to the bottom plate by van der Waals force.5. The apparatus of claim 4 , wherein a vertical pattern is formed in case the reflection coefficient of the cover is 0.15 or above.6. The apparatus of claim 1 , wherein the standing wave adding means is a surface acoustic wave generating means or an ultrasound transducer.7. The apparatus of claim 6 , wherein the standing wave adding means comprises a substrate and at least a pair of IDT electrodes formed on the substrate.8. The apparatus of claim 7 , wherein the at least one pair of IDT electrodes is ...

MICROFLUIDIC DEVICE FOR CEREBROVASCULAR SIMULATION AND HIGH-EFFICIENCY BLOOD-BRAIN BARRIER SIMULATION SYSTEM COMPRISING SAME

The present disclosure provides a microfluidic device for simulating a blood-brain barrier and a blood-brain barrier simulation system including the same, and the microfluidic device includes: a first channel; a second channel which is adjacently connected to the first channel through one or more microholes and configured to culture neural stem cells; and a chamber which is connected to both ends of the first channel and contains a culture medium. 1. A microfluidic device for simulating a neurovascular unit , comprising:a first channel;a second channel which is adjacently connected to the first channel through one or more microholes and configured to culture neural stem cells; anda chamber which is connected to both ends of the first channel and contains a culture medium.2. The microfluidic device of claim 1 ,wherein an inner surface of the first channel is coated with a coating solution containing at least one selected from the group consisting of poly-L-lysine and collagen.3. The microfluidic device of claim 1 , further comprising:endothelial cells adhered and cultured on an inner surface of the first channel.4. The microfluidic device of claim 3 , further comprising:pericytes adhered and cultured on lower ends of the endothelial cells and the inner surface of the first channel.5. The microfluidic device of claim 1 ,wherein the second channel includes a hydrogel for culturing the neural stem cells in three dimensions.6. The microfluidic device of claim 1 ,wherein the hydrogel includes collagen and crosslinked or non-crosslinked hyaluronic acid.7. The microfluidic device of claim 6 ,wherein the concentration of the collagen in the hydrogel is from 3.0 mg/ml to 5.0 mg/ml, and the concentration of the crosslinked or non-crosslinked hyaluronic acid in the hydrogel is from 1.0 mg/ml to 10.0 mg/ml.9. The microfluidic device of claim 1 ,wherein the culture medium is a medium in which an EGM-2 basal medium and a DMEM/F12 basal medium are mixed.10. The microfluidic device ...

COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof. 1. A composition for cleaving target DNA in eukaryotic cells or organisms comprising a guide RNA specific for target DNA or DNA that encodes the guide RNA , and Cas protein-encoding nucleic acid or Cas protein.2. The composition of claim 1 , wherein the target DNA is an endogenous target DNA.3. The composition of claim 1 , wherein the guide RNA is a dualRNA comprising a crRNA and a tracrRNA.4. The composition of claim 1 , wherein the guide RNA is a single-chain guide RNA (sgRNA).5. The composition of claim 4 , wherein the single-chain guide RNA comprises portion of a crRNA and a tracrRNA.6. The composition of claim 1 , wherein the guide RNA further comprises one or more additional nucleotides at the 5′ end of the single-chain guide RNA or the crRNA of the dualRNA.7. The composition of claim 1 , wherein the guide RNA further comprises 2 additional guanine nucleotides at the 5′ end of the single-chain guide RNA or the crRNA of the dualRNA.8. The composition of claim 1 , which induces targeted mutagenesis in eukaryotic cells or organisms.9. The composition of claim 1 , for use in the genotyping of a genome in the eukaryotic cells or organisms in vitro.10. The composition of claim 1 , wherein the guide RNA and the Cas protein function as a pair claim 1 , and wherein the pair comprises two guide RNAs which induce two nicks on different strands.11agrobacterium. The composition of claim 1 , wherein the guide RNA is in the form of an isolated RNA claim 1 , or is encoded in a vector claim 1 , wherein the vector is a viral vector claim 1 , plasmid vector claim 1 , or vector.12. The composition of claim 1 , comprising a guide RNA specific for ...

GENE CARRIER USING CELL-DERIVED NANOVESICLES AND METHOD FOR PREPARING THE SAME

Provided are a gene carrier using cell-derived nanovesicles and a method for preparing the same. The gene carrier prepared by inserting a gene into the nanovesicles artificially outbudded from a plasma membrane has excellent delivery efficiency to a target organ and cells, induces long-term regulation of gene expression, and facilitates mass production due to a simple preparation process, and thus can be used as a core technique for the gene or cell therapeutic agent field. 1. A method for preparing a gene carrier , comprising:(a) preparing nanovesicles by extruding a suspension containing vesicles outbudded from cells; and(b) inserting a nucleotide into the prepared nanovesicles,wherein the vesicles are outbudded by being cultured in a buffer solution containing paraformaldehyde (PFA) and dithiothreitol (DTT), andthe nucleotide is selected from the group consisting of mRNA, tRNA, rRNA, siRNA, and miRNA.2. The method of claim 1 , wherein claim 1 , before Step (a) claim 1 , overexpressing a targeting ligand in the cells.3. The method of claim 1 , wherein the cells are selected from the group consisting of human embryonic kidney-293 (HEK-293) cells claim 1 , human adipose-derived stem cells claim 1 , bone marrow stem cells claim 1 , dermal cells claim 1 , and blood cells.4. The method of claim 1 , wherein the buffer solution contains 25 to 50 mM PFA and 1 to 5 mM DTT.5. A gene carrier prepared by the method of .6. The gene carrier of claim 5 , wherein the gene carrier has a nucleotide enclosed in nanovesicles.7. The gene carrier of claim 5 , wherein the gene carrier has a diameter of 100 to 200 nm.8. The gene carrier of claim 5 , wherein the gene carrier further includes a targeting ligand.9. The gene carrier of claim 8 , wherein the targeting ligand is E-cadherin.10. A method for preparing a gene carrier claim 8 , comprising:(a) preparing microvesicles by centrifuging a suspension containing vesicles outbudded from cells;(b) treating the microvesicles with a ...

Highly efficient organoid culture device and system

The present invention provides an organoid culture device, comprising at least one first chamber for storing a culture medium; at least one second chamber for culturing an organoid; and a channel that interconnects adjacent chambers.

COMPOSITION FOR CULTURING BRAIN ORGANOID BASED ON DECELLULARIZED BRAIN MATRIX AND METHOD FOR PREPARING SAME

Provided is a method for preparing a composition for culturing a brain organoid, the method comprising (a) decellularizing brain tissue; (b) drying the brain tissue; and (c) gelating the brain tissue. 1. A method for preparing a composition for culturing a brain organoid , comprising:(a) decellularizing brain tissue;(b) drying the brain tissue; and(c) gelating the brain tissue.2. The method according to claim 1 ,wherein in the (c), the brain tissue and Matrigel are mixed to obtain a hydrogel.3. The method according to claim 2 ,wherein the hydrogel contains a decellularized brain extracellular matrix (dBEM) in an amount of 0.01 to 2.0 mg/mL.4. The method according to claim 1 ,wherein in the (a), the brain tissue is stirred in a decellularizing solution.5. The method according to claim 4 ,wherein the brain tissue is stirred for 3 to 24 hours.6. The method according to claim 4 ,wherein 95% or more of cells of the brain tissue is removed by the decellularization.7. A hydrogel composition for culturing a brain organoid claim 4 , comprising:a decellularized brain extracellular matrix (dBEM).8. The hydrogel composition according to claim 7 , further comprising:Matrigel.9. The hydrogel composition according to claim 7 ,wherein the decellularized brain extracellular matrix (dBEM) has a concentration of 0.01 to 2.0 mg/mL.10. The hydrogel composition according to claim 7 , which has an elastic modulus at 1 Hz of 100 to 150 Pa.11. A method for culturing a brain organoid in the composition of . The present invention relates to a composition for culturing a brain organoid using a decellularized brain matrix and a method for preparing the same.Decellularization of tissues and organs has been studied as a promising approach for preparing a functional support or scaffold for cell culture and transplantation.During a decellularization process, cellular components are removed from the tissue, but the extracellular matrix and some growth factor proteins are preserved.Therefore, various ...

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The invention provides a method of introducing double-stranded breaks into a target DNA in a mammalian cell, the method comprising contacting the target DNA with a type II CRISPR/Cas9 system comprising (a) Cas9 protein with one nuclear localization signal added to the C-terminus of the Cas9 protein; and (b) a single-chain guide RNA comprising a crRNA portion fused to a tracrRNA portion, wherein the method is not for treatment of the human or animal body by surgery or therapy, and wherein the method does not modify the germline genetic identity of human beings. The invention further provides a mammalian cell comprising said type II CRISPR/Cas9 system and a method of preparing said mammalian cell.

Intermediate connection structure of power cable

The present disclosure relates to a power cable and an intermediate connection structure, for connection thereof, which is capable of preventing the concentration of stress on a soldered part, which is configured to join a metal sheath of the power cable and a metal sheath restoration layer of the intermediate connection structure while ensuring airtight or watertight sealing therebetween, preventing deformation of or damage to the soldered part due to stress applied thereto, and minimizing thermal history in the power cable during the formation of the soldered part.

Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof.

Hydrogel using, as substrate, hyaluronic acid derivative modified with gallol group and use thereof

Gene carrier using cell-derived nanovesicles and method for preparing the same

Provided are a gene carrier using cell-derived nanovesicles and a method for preparing the same. The gene carrier prepared by inserting a gene into the nanovesicles artificially outbudded from a plasma membrane has excellent delivery efficiency to a target organ and cells, induces long-term regulation of gene expression, and facilitates mass production due to a simple preparation process, and thus can be used as a core technique for the gene or cell therapeutic agent field.

Harmonic rejection mixer and radio frequency receiver using the mixer

A mixer used in a Radio Frequency (RF) receiver is provided. The mixer includes a first harmonic rejecter for rejecting a harmonic signal component from a first input signal; and a second harmonic rejecter for rejecting a harmonic signal component from a second input signal. The first harmonic rejecter and the second harmonic rejecter are connected in parallel to reject an image signal component from the first input signal and the second input signal. Thus, the RF receiver can reject the harmonic signal and the image signal without using an external element.

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The invention provides a Type II Clustered Regularly interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) composition for use as a medicament, for example, in gene therapy, wherein the Type II CRISPR/Cas9 composition comprises: (a) a Cas9 protein, or a nucleic acid encoding the Cas9 protein; and (b) a single-chain guide RNA comprising a CRISPR RNA (crRNA) portion fused to a trans-activating crRNA (tracrRNA) portion. The invention further provides an in vitro method of cleaving a target DNA in a mammalian cell by introducing into the cell the Type II CRISPR/Cas9 composition of the invention.

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

Hydrogel using, as substrate, hyaluronic acid derivative modified with gallol group and use thereof

The present invention provides a hydrogel platform using, as a substrate, hyaluronic acid (HA) conjugated to a pyrogallol (PG) moiety. The HA-PG conjugate of the present invention can be promptly crosslinked by two different methods, such as using an oxidant or adjusting pH. The hydrogel of the present invention can efficiently control physical characteristics, such as a crosslinking rate, elasticity, and adhesive strength, according to the crosslinking manner of each, while having excellent biocompatibility. The hydrogel of the present invention can be used, on the basis of such excellent stability and functionality thereof, in various fields including drug delivery, biopharmaceutical materials such as a wound healing agent or anti-adhesive agent, medicines, and cosmetic products.

Hydrogel of chondroitin sulfate functionalized with phenol derivative and use thereof

The present disclosure relates to a hydrogel including chondroitin sulfate functionalized with a phenol derivative, and a composition for cell culture, a composition for promoting cell differentiation, a composition for drug delivery, a composition for promoting tissue regeneration and a composition for tissue transplant, each including the hydrogel. The hydrogel can be advantageously used in the field of tissue engineering.

Heart extracellular matrix-derived scaffold for culture and transplantation of cardiac organoid and method of preparing the same

The present disclosure relates to a scaffold for culturing and transplanting a cardiac organoid by using a heart extracellular matrix (HEM).

Microfluidic device for cerebrovascular simulation and high-efficiency blood-brain barrier simulation system comprising same

The present disclosure provides a microfluidic device for simulating a blood-brain barrier and a blood-brain barrier simulation system including the same, and the microfluidic device includes: a first channel; a second channel which is adjacently connected to the first channel through one or more microholes and configured to culture neural stem cells; and a chamber which is connected to both ends of the first channel and contains a culture medium.

Cell-free process for the production of post-translationally modified proteins

Extracellular matrix-loaded bio-inspired tissue-adhesive hydrogel patch

The present disclosure relates to a hydrogel patch, including: a hydrogel patch containing a biocompatible polymer functionalized with a phenol group; and an extracellular matrix loaded in the hydrogel patch.

Tissue gell for transplantation using decellularized extracellular matrix and method of preparing the same

Provided is a tissue gel for transplantation and a method of preparing the same, including: a process (a) of preparing a composition containing a decellularized extracellular matrix; a process (b) of maintaining a tensile state by applying a tensile force to a stretching device made of an elastic polymer material; and a process (c) of injecting the composition prepared in the process (a) into the stretching device maintained in the tensile state in the process (b), allowing the composition to crosslink, and then removing the tensile force to align fibrils in the decellularized extracellular matrix in one direction.

Tissue gel for transplantation using decellularized extracellular matrix and method for producing same

The present disclosure relates to a tissue gel for transplantation and a method of preparing the same, including: a process (a) of preparing a composition containing a decellularized extracellular matrix; a process (b) of maintaining a tensile state by applying a tensile force to a stretching device made of an elastic polymer material; and a process (c) of injecting the composition prepared in the process (a) into the stretching device maintained in the tensile state in the process (b), allowing the composition to crosslink, and then removing the tensile force to align fibrils in the decellularized extracellular matrix in one direction.

Tissue-derived extracellular matrix derivative modified with acryl group and use thereof

The present invention relates to a tissue-derived extracellular matrix derivative modified with an acryl group and a use thereof. A composition for a hydrogel and a hydrogel prepared therefrom of the present invention can simulate fibrosis patterns of A various tissues according to the degree of modification or crosslinking.

Phenol derivative-modified, tissue-derived extracellular matrix derivative for construction of artificial tissue

A phenol derivative-modified, tissue-derived extracellular matrix derivative for construction of artificial tissues. A hydrogel composition and a hydrogel prepared therefrom exhibit various effects such as hemostasis, blood coagulation acceleration, cell transplantation, drug delivery, cell differentiation promotion, etc. and thus can be applied to single or composite uses. Furthermore, the present invention is excellent in biocompatibility due to its biodegradability and being almost free of cytotoxicity, thus exhibiting very high applicability. In addition, a tissue structure including a single type or multiple types of cells can be formed through the cell-proliferating potential and adhesion of the hydrogel and can better simulate in-vivo microenvironments.

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The invention provides a composition for inducing targeted mutagenesis of an endogenous DNA in a eukaryotic cell, the composition comprising: a Cas9 protein; and a guide RNA, wherein the guide RNA comprises a CR!SPR RNA (crRNA) and a transactivating crRNA (tracrRNA), wherein the crRNA comprises a portion that hybridizes with a target DNA, wherein the target DNA is the endogenous DNA of the eukaryotic cell; and wherein the Cas9 protein is complexed with the guide RNA to form an active endonuclease before being introduced into the eukaryotic cell. The invention further provides for use of the composition for targeted mutagenesis in a eukaryotic cell, a kit for cleaving a target DNA in a eukaryotic cell, a method for inducing targeted mutagenesis of an endogenous DNA in a eukaryotic cell, and a cell comprising the composition of the invention.

Microfluidic hanging drop culture device for culturing cell aggregates

The present invention relates to a microfluidic hanging drop culture device for culturing cell aggregates, and organoids/spheroids cultured in the device of the present invention have greater stem cell activity and higher differentiation than organoids/spheroids of a conventional culture technology. The present invention can be reused repeatedly, and can be utilized as platforms according to various uses by changing the size and number of wells, and by using a rocker in the device, a culture solution located in wells in a reservoir and a culture chamber is allowed to continuously flow through microchannels so that the environment of all of the wells is maintained to be the same, and thus cell aggregates can be cultured with high efficiency. In addition, the device for culturing cell aggregates can be used as a model for disease research and drug screening through the mass-production of cell aggregates of which disease phenotypes are maintained, and can also be used in transplantation therapy for treating diseases through the mass-production of therapeutic cell aggregates.

Pancreas extracellular matrix derived scaffold for culture and transplantation of pancreatic organoid and method of preparing the same

The present disclosure relates to a scaffold for culture and transplantation of a pancreatic organoid by using a decellularized pancreatic tissue (pancreas extracellular matrix; PEM).

Esophagus extracellular matrix-derived scaffold for culture and transplantation of esophageal organoid, and method of preparing the same

The present disclosure relates to a scaffold for culture and transplantation of an esophageal organoid by using a decellularized esophageal tissue (esophagus extracellular matrix; EEM).

Scaffold derived from decellularized adipose tissue for culturing organoid, and method for producing same

The present disclosure relates to a decellularized adipose tissue-derived scaffold and a method of preparing the same. The scaffold of the present disclosure can be applied to culture of various types of organoids and thus can be used in various fields due to its high versatility. Also, the scaffold of the present disclosure can be prepared from a human adipose tissue to be discarded and thus can create enormous added value. Further, the scaffold of the present disclosure can be widely used in the medical industry, such as new drug development, drug toxicity and efficacy evaluation, and patient-specific drug selection, in substitution for conventional Matrigel.

Adipose extracellular matrix-derived scaffold for culturing organoid and preparing method thereof

The present disclosure relates to a decellularized adipose tissue-derived scaffold and a method of preparing the same. The scaffold of the present disclosure can be applied to culture of various types of organoids and thus can be used in various fields due to its high versatility. Also, the scaffold of the present disclosure can be prepared from a human adipose tissue to be discarded and thus can create enormous added value. Further, the scaffold of the present disclosure can be widely used in the medical industry, such as new drug development, drug toxicity and efficacy evaluation, and patient-specific drug selection, in substitution for conventional Matrigel.

Kidney extracellular matrix-derived scaffold for culture and transplantation of kidney organoid and method of preparing the same

The present disclosure relates to a scaffold for culture and transplantation of a kidney organoid using a decellularized kidney tissue (KEM).

Composition for culturing brain organoid based on decellularized brain matrix and method for preparing same

Provided is a method for preparing a composition for culturing a brain organoid, the method comprising (a) decellularizing brain tissue; (b) drying the brain tissue; and (c) gelating the brain tissue.

Allulose epimerase variant with excellent thermal stability, preparation method therefor, and preparation method for allulose using same

The present invention provides a novel allulose epimerase variant in which an amino acid residue present at a specific position of an amino acid sequence of wild-type D-allulose 3-epimerase derived from Flavonifractor plautii is substituted with another amino acid residue, and various uses thereof. The novel allulose epimerase variant according to the present invention has a higher conversion activity of fructose to allulose than that of the wild-type D-allulose 3-epimerase derived from Flavonifractor plautii or a D-allulose epimerase variant W29K/G216S/M234I, and has excellent thermal stability especially under high temperature conditions of 60° C. or higher, thereby preventing contamination during an industrial-scale enzymatic conversion reaction for the mass production of allulose, shortening the production time, and reducing the production costs.

Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells

The present disclosure relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present disclosure provides for Cas9/RNA complexes that may induce modifications in target endogenous nucleic acid sequences in nucleuses of eukaryotic cells. The Cas9/RNA complex may comprise a recombinant Cas9 protein including a nuclear localization signal (NLS) and a guide RNA including a crRNA and a tracrRNA. The Cas9/RNA complex may be a combination of the recombinant Cas9 protein and the guide RNA. The guide RNA may be transcribed in vitro or synthesized chemically. The target endogenous nucleic acid sequence may include a portion complementary to the crRNA of the guide RNA.

Decellularized tissue-derived extracellular matrix functionalized with phenol derivative and use thereof

The present disclosure relates to a hydrogel including a decellularized tissue-derived extracellular matrix functionalized with a phenol derivative, and a composition for cell culture, a composition for promoting cell differentiation, a tissue adhesive composition, a composition for drug delivery, a composition for promoting tissue regeneration and a composition for tissue implantation, each including the hydrogel. The hydrogel can be usefully used in the field of tissue engineering.

Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells

The present disclosure relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present disclosure provides compositions for inducing targeted disruption of endogenous genes in eukaryotic cells. The composition may comprise a Cas9/guide RNA complex with a Cas9 protein to which a NLS is linked, and a guide RNA having a crRNA and a tracrRNA. The crRNA may comprise i) a portion to be hybridized with a portion of the tracrRNA, and ii) a portion complementary to a target DNA of the endogenous genes. In some embodiments, the Cas/guide RNA complex may be formed in vitro before being introduced into the eukaryotic cell.

標的ｄｎａに特異的なガイドｒｎａおよびｃａｓタンパク質コード核酸またはｃａｓタンパク質を含む、標的ｄｎａを切断するための組成物、ならびにその使用

【課題】真核細胞内における内在性遺伝子の標的破壊を誘発するための組成物および方法を提供する。【解決手段】Cas9/RNA複合体を含む、真核細胞内における内在性遺伝子の標的破壊を誘発するための組成物であって、前記Cas9/RNA複合体は、１つ以上のタグ配列に結合されたCas9タンパク質、ここで、前記タグ配列は核局在化シグナル（NLS）を含む；およびCRISPR RNA（crRNA）およびトランス活性化crRNA（tracrRNA）を有するガイドRNA、ここで、crRNAは、i)tracrRNAの部分とハイブリダイズされる部分、および、ii)内在性遺伝子の標的DNAと相補的な部分を含む、を含み、Cas9タンパク質は、真核細胞内に導入される前にガイドRNAと複合体化されてリボ核タンパク質を形成し、リボ核タンパク質は、標的DNAの標的破壊を誘発するエンドヌクレアーゼとして働く、前記組成物とする。【選択図】図１ａ

標的ｄｎａに特異的なガイドｒｎａおよびｃａｓタンパク質コード核酸またはｃａｓタンパク質を含む、標的ｄｎａを切断するための組成物、ならびにその使用

【課題】真核細胞の核内の標的内在性核酸配列の改変を誘発するための組成物及び方法を提供する。【解決手段】Cas9/RNA複合体を含む、真核細胞の核内の標的内在性核酸配列の改変を誘発するための組成物であって、複合体は、組換えCas9タンパク質；およびcrRNAおよびtracrRNAを含むガイドRNAを含み、Cas9/RNA複合体は、組換えCas9タンパク質とガイドRNAの組合せであって、組合せは、組換えCas9タンパク質およびガイドRNAをin vitroで混合およびインキュベートすることにより組み立てられ、ガイドRNAはin vitroで転写されるか化学的に合成され、標的内在性核酸配列はガイドRNAのcrRNAに相補的な部分を含み、組換えCas9タンパク質とガイドRNAの組合せは真核細胞に導入されて、真核細胞の核内の標的内在性核酸配列の改変を引き起こす、前記組成物とする。【選択図】図１ａ

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof.

Decellularized tissue-derived extracellular matrix modified with phenol derivative and use thereof

The present disclosure relates to a hydrogel including a decellularized tissue-derived extracellular matrix functionalized with a phenol derivative, and a composition for cell culture, a composition for promoting cell differentiation, a tissue adhesive composition, a composition for drug delivery, a composition for promoting tissue regeneration and a composition for tissue implantation, each including the hydrogel. The hydrogel can be usefully used in the field of tissue engineering.

Phenol derivative-modified, tissue-derived extracellular matrix derivative for construction of artificial tissue

The present invention relates to a phenol derivative-modified, tissue-derived extracellular matrix derivative for construction of artificial tissues. A hydrogel composition of the present invention and a hydrogel prepared therefrom exhibit various effects such as hemostasis, blood coagulation acceleration, cell transplantation, drug delivery, cell differentiation promotion, etc. and thus can be applied to single or composite uses. Furthermore, the present invention is excellent in biocompatibility due to its biodegradability and being almost free of cytotoxicity, thus exhibiting very high applicability. In addition, a tissue structure including a single type or multiple types of cells can be formed through the cell-proliferating potential and adhesion of the hydrogel of the present invention and can better simulate in-vivo microenvironments.

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof.

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof.

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas9 protein, and uses thereof.

Microfluidic hanging drop culture device for culturing cell aggregate

The present invention relates to a microfluidic hanging drop culture device for culturing cell aggregates, and organoids/spheroids cultured in the device of the present invention have greater stem cell activity and higher differentiation than organoids/spheroids of a conventional culture technology. The present invention can be reused repeatedly, and can be utilized as platforms according to various uses by changing the size and number of wells, and by using a rocker in the device, a culture solution located in wells in a reservoir and a culture chamber is allowed to continuously flow through microchannels so that the environment of all of the wells is maintained to be the same, and thus cell aggregates can be cultured with high efficiency. In addition, the device for culturing cell aggregates can be used as a model for disease research and drug screening through the mass-production of cell aggregates of which disease phenotypes are maintained, and can also be used in transplantation therapy for treating diseases through the mass-production of therapeutic cell aggregates.

Non-alcoholic fatty liver artificial tissue model

The present disclosure relates to a non-alcoholic fatty liver artificial tissue model. As compared to a conventional technology by which tissues are cultured only in Matrigel including a device composed of a decellularized liver tissue-derived extracellular matrix and a plurality of microchannels or a decellularized liver tissue-derived extracellular matrix, the present disclosure enables better mimicking of an actual non-alcoholic fatty liver disease due to the presence of Kupffer cells and hepatic stellate cells. Also, according to the present disclosure, the growth of liver organoids can be improved and fat accumulation and inflammation in the liver organoids can be caused to occur well through free fatty acid treatment, and the phenotypes of non-alcoholic fatty liver can be better expressed.

Phenol derivative-functionalized chondroitin sulfate hydrogel and use of same

Decellularized heart extracellular matrix-derived scaffold for culturing and transplanting heart organoid, and preparation method therefor

Pectin modified with gallol derivative and use thereof

The present invention is intended to provide a hydrogel that utilizes the naturally occurring substance pectin to exhibit an equivalent or greater effect. Specifically, the present application is intended to provide a hydrogel or a patch which is stable, has strong adhesive strength, is advantageous for drug delivery, can be used for sustained treatment, has extremely low cytotoxicity, and is unlikely to induce an immune response, and thus can be used on various body parts, in particular the oral cavity. In addition, the present invention is intended to provide a hydrogel patch which employs a freezing method prior to crosslinking, and thus exhibits superior adhesion to patches employing a post-crosslinking freezing method.

Pectin modified with gallol derivative and use thereof

The provided is a hydrogel that utilizes the naturally occurring substance pectin to exhibit an equivalent or greater effect. Specifically, the present application is intended to provide a hydrogel or a patch which is stable, has strong adhesive strength, is advantageous for drug delivery, can be used for sustained treatment, has extremely low cytotoxicity, and is unlikely to induce an immune response, and thus can be used on various body parts, in particular the oral cavity. In addition, the provide is a hydrogel patch which employs a freeze-drying method prior to crosslinking, and thus exhibits superior adhesion to patches employing a post-crosslinking freeze-drying method.

Allulose epimerase variant, method for producing same, and method for producing allulose using same

Composition for inducing death of cells having mutated gene, and method for inducing death of cells having modified gene by using composition

Pancreatic extracellular matrix-derived support for pancreatic organoid culture and transplantation, and method for preparing same

The present disclosure relates to a scaffold for culture and transplantation of a pancreatic organoid by using a decellularized pancreatic tissue (pancreas extracellular matrix; PEM).

Non-alcoholic fatty liver artificial tissue model

The present disclosure relates to a non-alcoholic fatty liver artificial tissue model. As compared to a conventional technology by which tissues are cultured only in Matrigel including a device composed of a decellularized liver tissue-derived extracellular matrix and a plurality of microchannels or a decellularized liver tissue-derived extracellular matrix, the present disclosure enables better mimicking of an actual non-alcoholic fatty liver disease due to the presence of Kupffer cells and hepatic stellate cells. Also, according to the present disclosure, the growth of liver organoids can be improved and fat accumulation and inflammation in the liver organoids can be caused to occur well through free fatty acid treatment, and the phenotypes of non-alcoholic fatty liver can be better expressed.

Scaffold derived from decellularized organ tissue, for organ organoid culture and transplantation, and production method therefor

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The invention provides a composition for inducing targeted mutagenesis of an endogenous DNA in a eukaryotic cell, the composition comprising: a Cas9 protein; and a guide RNA, wherein the guide RNA comprises a CR!SPR RNA (crRNA) and a transactivating crRNA (tracrRNA), wherein the crRNA comprises a portion that hybridizes with a target DNA, wherein the target DNA is the endogenous DNA of the eukaryotic cell; and wherein the Cas9 protein is complexed with the guide RNA to form an active endonuclease before being introduced into the eukaryotic cell. The invention further provides for use of the composition for targeted mutagenesis in a eukaryotic cell, a kit for cleaving a target DNA in a eukaryotic cell, a method for inducing targeted mutagenesis of an endogenous DNA in a eukaryotic cell, and a cell comprising the composition of the invention.

Compounds, compositions containing same, and use thereof for promoting hair growth

Provided are preparation and use of novel compounds available as main ingredients of a composition for promoting hair growth, wherein the novel compounds are 9-deoxo-31-O-demethyl-prolyl-FK506, 9-deoxo-36,37-dihydro-FK506, 31-O-demethyl-36,37-dihydro-FK506, 9-deoxo-31-O-demethyl-36,37-dihydro-FK506, 9-deoxo-FK520, 31-O-demethyl-FK520, 9-deoxo-31-O-demethyl-FK520, 9-deoxo-FK523, and 9-deoxo-31-O-demethyl-FK523.

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas9 protein, and uses thereof.

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas9 protein, and uses thereof.

Multi-organ model

The present disclosure relates to a multi-organ model, and the multi-organ model of the present disclosure is excellent in culturing each organoid due to linkage between organoids and properties of hydrogel and can more accurately reflect the interactions between organs and the microenvironment in vivo. Also, the multi-organ model is further subjected to free fatty acid treatment and thus can more accurately mimic the phenotypes of non-alcoholic fatty liver. Accordingly, it is possible to analyze the effects of candidate drugs on peripheral organs.

Non-alcoholic fatty liver artificial tissue model

The present disclosure relates to a non-alcoholic fatty liver artificial tissue model. As compared to a conventional technology by which tissues are cultured only in Matrigel including a device composed of a decellularized liver tissue-derived extracellular matrix and a plurality of microchannels or a decellularized liver tissue-derived extracellular matrix, the present disclosure enables better mimicking of an actual non-alcoholic fatty liver disease due to the presence of Kupffer cells and hepatic stellate cells. Also, according to the present disclosure, the growth of liver organoids can be improved and fat accumulation and inflammation in the liver organoids can be caused to occur well through free fatty acid treatment, and the phenotypes of non-alcoholic fatty liver can be better expressed.

Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof.

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas9 protein, and uses thereof.

Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells

The present disclosure relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present disclosure provides for Cas9/RNA complexes that may induce modifications in target endogenous nucleic acid sequences in nucleuses of eukaryotic cells. The Cas9/RNA complex may comprise a recombinant Cas9 protein including a nuclear localization signal (NLS) and a guide RNA including a crRNA and a tracrRNA. The Cas9/RNA complex may be a combination of the recombinant Cas9 protein and the guide RNA. The guide RNA may be transcribed in vitro or synthesized chemically. The target endogenous nucleic acid sequence may include a portion complementary to the crRNA of the guide RNA.

Allulose epimerase variant with excellent thermal stability, preparation method therefor, and preparation method for allulose using same

The present invention provides a novel allulose epimerase variant in which an amino acid residue present at a specific position of an amino acid sequence of wild-type D-allulose 3-epimerase derived from Flavonifractor plautii is substituted with another amino acid residue, and various uses thereof. The novel allulose epimerase variant according to the present invention has a higher conversion activity of fructose to allulose than that of the wild-type D-allulose 3-epimerase derived from Flavonifractor plautii or a D-allulose epimerase variant W29K/G216S/M234I, and has excellent thermal stability especially under high temperature conditions of 60°C or higher, thereby preventing contamination during an industrial-scale enzymatic conversion reaction for the mass production of allulose, shortening the production time, and reducing the production costs.

Decellularized kidney extracellular matrix-derived scaffold for culturing and transplanting kidney organoid, and preparation method therefor

The present disclosure relates to a scaffold for culture and transplantation of a kidney organoid using a decellularized kidney tissue (KEM).

Esophagus extracellular matrix-derived scaffold for culturing and transplanting esophageal organoid, and method for producing same

The present disclosure relates to a scaffold for culture and transplantation of an esophageal organoid by using a decellularized esophageal tissue (esophagus extracellular matrix; EEM).

Ultrasound image device and ultrasound image generation method

A method of generating an ultrasound image includes: setting a focal point in an object; transmitting, based on a location of the focal point, ultrasound signals into the object by using a plurality of elements in a transducer; receiving, via the plurality of elements, ultrasound echo signals obtained by reflecting the ultrasound signals from the object; and performing beamforming on the received ultrasound echo signals, wherein the performing of the received ultrasound echo signals includes: setting, based on the location of the focal point, a plurality of delay times respectively corresponding to the plurality of elements; determining capacitors respectively corresponding to the plurality of elements based on the set plurality of delay times; and respectively performing the beamforming on the received ultrasound echo signals by using the determined capacitors.

Ultrasound image device and ultrasound image generation method

Exosomes-loaded biomimetic tissue-adhesive hydrogel patch

The present disclosure relates to a hydrogel patch, including: a hydrogel patch containing a biocompatible polymer functionalized with a phenol group; and an exosome loaded in the hydrogel patch.

Exosome-loaded bio-inspired tissue-adhesive hydrogel patch

The present disclosure relates to a hydrogel patch, including: a hydrogel patch containing a biocompatible polymer functionalized with a phenol group; and an exosome loaded in the hydrogel patch.

Biomimetic tissue-adhesive hydrogel patch for preventing or treating cartilage or bone diseases

Tissue-derived extracellular matrix derivative modified with acryl group and use thereof

The present invention relates to a tissue-derived extracellular matrix derivative modified with an acryl group and a use thereof. A composition for a hydrogel and a hydrogel prepared therefrom of the present invention can simulate fibrosis patterns of {circumflex over ( )} various tissues according to the degree of modification or crosslinking.

Hydrogel including phenol derivative-modified cellulose and use thereof

A hydrogel including phenol derivative-modified cellulose, a use thereof, and a preparation method therefor are described. Physical properties of the hydrogel can be modulated by adjusting concentrations of and oxidation conditions for the phenol derivative-modified cellulose. In addition, the hydrogel of the present invention can find applications in various fields due to its properties, such as hemostasis, blood coagulation acceleration, tissue adhesion, cell culture, cell transplantation, drug delivery, etc.

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas9 protein, and uses thereof.

Decellularized tissue-derived extracellular matrix modified with phenol derivative and use thereof

Exosomes-loaded biomimetic tissue-adhesive hydrogel patch

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas9 protein, and uses thereof.

Extracellular matrix-supported biomimetic tissue adhesive hydrogel patch